Most people expect semaglutide to feel different from day one. It doesn't. The first month is almost entirely about tolerability — getting your body accustomed to the medication before the dose that actually drives significant weight loss. This guide covers the honest week-by-week timeline from the STEP clinical trials plus what real patients report, what affects your individual speed, and what to do if it's not working on your expected schedule.
The short answer — by week and month
| Timeframe | Dose | What most people experience | STEP trial avg weight loss |
|---|---|---|---|
| Week 1–4 | 0.25mg/week | Subtle appetite reduction. Some nausea. Minimal weight change. | ~1–2% |
| Week 5–8 | 0.5mg/week | Clear appetite suppression begins. "Food noise" quiets. 2-5 lbs lost. | ~3–4% |
| Week 9–12 | 1.0mg/week | Consistent weekly losses. Portion sizes naturally reduce. Energy improving. | ~5–7% |
| Week 13–16 | 1.7mg/week | Rapid phase for many patients. Others starting to notice visibly. | ~7–9% |
| Week 17+ | 2.4mg/week | Maximum dose. Sustained losses. Plateau begins for most at some point. | ~10–15% |
| Week 64–68 | 2.4mg/week | End of STEP-1 trial. Maximum documented average effect. | 14.9% avg |
Complete week-by-week timeline
The tolerance-building phase — almost nothing happens here
The 0.25mg starting dose is your body's introduction to GLP-1 receptor activation. Most patients report mild nausea on injection day, slightly reduced appetite, and 0-3 lbs of weight change over 4 weeks. The food cravings and patterns you're used to are still largely present. This is not a sign the medication isn't working — it's working exactly as designed, which is to slowly introduce you before stepping to therapeutic doses. Some patients do lose 4-8 lbs in week 1-4, particularly if their diet changes significantly with the prescription.
First meaningful appetite suppression — the "food noise" quiets
At 0.5mg, most patients have their first clear experience of what semaglutide actually does: the constant background mental chatter about food — what to eat next, cravings, thinking about meals — begins to quiet. Patients call this "food noise going away." Portion sizes naturally reduce because meals feel satisfying earlier. Most patients lose 3-6 lbs in these 4 weeks. Side effects (nausea, constipation) often peak here before improving.
Consistent weekly losses — the results become real
At 1mg, most patients are losing weight consistently week over week. The STEP-1 trial showed approximately 5.2% average cumulative weight loss at 12 weeks — for a 200 lb person, that's about 10 lbs. Energy typically improves as metabolic health responds. Side effects usually stabilize or improve from the week 5-8 peak. This is when most patients feel confident the medication is genuinely working for them.
Others notice — the transformation becomes visible
By month 4-5, most patients have lost 7-12% of starting body weight. For many, this is 15-25 lbs — enough that coworkers, friends, and family comment unprompted. The STEP trial showed 8.4% average at week 20. Appetite suppression is now fully established and feels automatic rather than effortful. Clothing fit has changed. Some patients reach their personal weight loss plateau earlier than the clinical average — this is common and not a failure.
The long game — continued loss and the plateau challenge
The rate of weekly weight loss typically slows in this phase — not because the medication stops working, but because your body now weighs less, so each week's deficit produces smaller absolute numbers. Most patients hit at least one plateau of 2-6 weeks during this period. The STEP-1 trial showed 12.4% average at 28 weeks. The plateau response: do not increase dose immediately. First assess protein intake, exercise, and sleep before assuming the current dose is insufficient.
Peak clinical outcome — 14.9% average at week 68
The STEP-1 trial ran to 68 weeks and found a 14.9% average total body weight loss at the 2.4mg maintenance dose. Top responders lose 20-25%+. Non-responders may see only 5-8%. Most patients reach their lowest weight somewhere between month 10-16, after which weight stabilizes on maintenance dosing. This is not weight regain — it's the natural stabilization point where appetite suppression and reduced caloric intake have balanced against lower bodyweight energy expenditure.
Ready to start your semaglutide timeline?
DirectMeds offers physician-supervised compounded semaglutide from $249/month — same active molecule as Wegovy. Free eligibility check, physician consultation included, ships in 1-2 days.
Check eligibility at DirectMeds →What affects how quickly semaglutide works for you
The STEP-1 average of 14.9% at 68 weeks represents the middle of a wide distribution. Some patients reach that number at month 8; others take 18 months. Six factors most consistently affect individual speed:
How long does semaglutide take to work for women — the hormonal factor
Women make up the majority of semaglutide users for weight loss, and they experience a distinct pattern that the general STEP trial data obscures: women in perimenopause and menopause often see slower initial results than the clinical average, with a significant acceleration when hormonal factors are addressed alongside the medication.
The mechanism: declining estrogen during the menopause transition promotes fat storage in the abdomen, reduces insulin sensitivity, and disrupts the hormonal environment that GLP-1 medications are working against. A woman on semaglutide who is also estrogen-deficient is in a metabolic tug-of-war. A 2026 Mayo Clinic study found that postmenopausal women combining hormone therapy with tirzepatide lost 35% more weight than those on tirzepatide alone — specifically because addressing the hormonal environment makes the GLP-1 medication more effective.
Women: are hormones slowing your semaglutide results?
If you're in your 40s or 50s and seeing slower results than expected, FemExcel evaluates all 6 hormones and creates a personalized plan that can work alongside your semaglutide treatment.
Start FemExcel hormone evaluation →What to do if semaglutide isn't working on your expected timeline
"I'm at week 4 and nothing is happening"
This is expected. Week 4 is still the 0.25mg starting dose — below therapeutic. Do not adjust dose or consider the medication a failure. Continue to week 8 at 0.5mg and reassess. Most patients don't feel significant results until week 5-8.
"I'm at month 3 and have lost only 5 lbs"
Month 3 at 5 lbs is below average but not alarming if you're still titrating. Check: are you getting 0.7-1g of protein per pound of bodyweight? Are you sleeping 7+ hours? Have you had a dose step-up since month 1? If you're at 1mg and have been for 8 weeks with only 5 lbs lost, discuss dose adjustment with your physician.
"I lost weight, then completely stopped — a plateau"
Plateaus of 2-6 weeks are normal and expected, even at maximum dose. Your body has adapted its resting metabolic rate to your new lower weight. Action: assess protein intake first, then add or increase resistance training, then evaluate sleep quality. Only after ruling out these three factors should you consider a dose adjustment or medication change.
"I'm at 2.4mg for 12+ weeks and have lost less than 5%"
This is the profile of a potential low responder — possibly GLP-1 receptor genetic variation. Discuss with your physician switching to tirzepatide (dual GLP-1/GIP agonist), which has a different mechanism and often produces results in semaglutide non-responders. Also assess hormonal factors if you're a woman 40+.
"Side effects are stopping me from progressing through the dose schedule"
Stay at your current dose for an additional 4-8 weeks rather than stepping up. Side effects — especially nausea — are dose-dependent and typically diminish with time at any given dose level. Forcing a step-up through significant side effects is the leading cause of GLP-1 medication discontinuation. Slow titration reaches the same endpoint with better outcomes.
How semaglutide timing compares to tirzepatide
If you're deciding between semaglutide and tirzepatide, the timeline comparison matters. Both follow once-weekly injection schedules with 4-week titration steps. The key differences in timing:
| Milestone | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Titration period | 16 weeks (0.25→2.4mg) | 20 weeks (2.5→15mg) |
| First appetite suppression | Week 2-3 (mild), Week 5-8 (clear) | Week 2-3 (often stronger first effects) |
| 10% weight loss | ~Month 8-10 for average responder | ~Month 6-8 for average responder |
| Average peak loss | 14.9% at 68 weeks | 22% at 72 weeks |
| Starting dose (compounded) | $249/month | $397/month |
Tirzepatide's dual GLP-1/GIP mechanism produces faster and larger results for most patients — but the titration period is 4 weeks longer and the starting cost is higher. For patients primarily focused on speed of results, tirzepatide is the stronger option. For patients prioritizing cost-effectiveness, semaglutide at $249/month produces meaningful 15% weight loss for most patients at a significantly lower price.